Partnering Strategy
NEURONAX’s lead candidate, NX210, is firstly developed as candidate-drug for the treatment of spinal cord injuries but various experimental results argue for additional indications such as stroke, Alzheimer’s and Parkinson’s diseases, myelin disorders…
In order to explore these potential applications, NEURONAX is continuously considering partnering and is currently seeking partners for out-licensing or co-development.
Current Partners
- University Hospital of Clermont-Ferrand: IGCNC
- CNRS UMR6247 -INSERM U931 – University of Auvergne
- University of Limoges
Moreover, NEURONAX is member of GIMRA, the Association of Pharmaceutical Manufacturers in Auvergne and of Analgesia Partnership, the first multidisciplinary platform dedicated to analgesics.
